Diagnostic and therapeutic applications of monoclonal antibodies in colorectal cancer

Diseases of the Colon and Rectum

Volumn 41, Issue 2, 1998, Pages 232-250

  Stocchi, Luca ^a   Nelson, Heidi ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Colorectal cancer; Immunoscintigraphy; Immunotherapy; Monoclonal antibody

Indexed keywords

MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; RADIOIMMUNODETECTION;

EID: 0031939359     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02238254     Document Type: Article

References (178)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
2. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879-85.
3. Haseman MK, Brown DW, Keeling CA, Reed NL. Radioimmunodetection of occult carcinoembryonic antigen-producing cancer. J Nucl Med 1992;33:1750-6.
4. Collier BD, Abdel-Nabi H, Doerr RJ, et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992;185:179-86.
5. Doerr RJ, Abdel-Nabi H, Krag D, Mitchell E. Radiolabeled antibody imaging in the management of colorectal cancer: results of a multicenter clinical study. Ann Surg 1991;214:118-24.
6. Steinstrasser A, Oberhausen E. Anti-CEA labelling kit BW 431/26: results of the European multicenter trial. Nuklearmedizin 1995;34:232-42.
7. Corman ML, Galandiuk S, Block GE, et al. Immunoscintigraphy with 111In-satumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management. Dis Colon Rectum 1994;37:129-37.
8. Dillman RO, Shawler DL, McCallister TJ, Halpern SE. Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies. Cancer Bioth 1994;9:17-28.
9. Lind P, Lechner P, Arian-Schad K, et al. Anti-carcinoembryonic antigen immunoscintigraphy (technetium-99m-monoclonal antibody BW 431/26) and serum CEA levels in patients with suspected primary and recurrent colorectal carcinoma. J Nucl Med 1991;32: 1319-25.
10. Abdel-Nabi HH, Doerr RJ, Chan HW, et al. Safety and role of repeated administrations of Indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE 025 in the postoperative follow-up of colorectal carcinoma patients. J Nucl Med 1992;33:14-22.
11. Frodin JE, Lefvert AK, Mellstedt H. Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules. Cancer Res 1990;50:4866-71.
12. Colcher D, Milenic DE, Ferroni P, et al. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med 1990;31:1133-42.
13. Ledermann JA, Begent RH, Massof C, Kelly AM, Adam T, Bagshawe KD. A phase-I study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin A to suppress the immune response. Int J Cancer 1991;47:659-64
14. Dhingra K, Fritsche H, Murray JL, et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995;55;3060-7.
15. Morton BA, O'Connor-Tressel M, Beatty BG, Shively JE, Beatty JD. Artifactual CEA elevation due to human anti-mouse antibodies. Arch Surg 1988;123:1242-6.
16. Hansen HJ, LaFontaine G, Newman ES, et al. Solving the problem of antibody interference in commercial "sandwich"-type immunoassays of carcinoembryonic antigen. Clin Chem 1989;35:146-51.
17. Newman ES, Moskie LA, Duggal RN, Goldenberg DM, Hansen HJ. Murine monoclonal antibody adsorbed onto vinylidene fluoride floccules used to eliminate antibody interference in "sandwich"-type immunoassays. Clin Chem 1989;35:1743-6.
18. Koprowski H, Herlyn D, Lubeck M, DeFreitas E, Sears HF. Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient? Proc Natl Acad Sci U S A 1984;81:216-9.
19. Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA, Kohler H. Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990;145: 2758-65.
20. Fagerberg J, Hjelm AL, Ragnhammar P, Frodin JE, Wigzell H, Mellstedt H. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995;55:1824-7.
21. Sun LK, Curtis P, Rakowicz-Szulczynska E, et al. Chimeric antibodies with 17-1A-derived variable and human constant regions. Hybridoma 1986;5(Suppl 1): S17-20.
22. Morrison SL. Transfectomas provide novel chimeric antibodies. Science 1985;229:1202-7.
23. Velders MP, Litvinov SV, Warnaar SO, et al. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994;54:1753-9.
24. Hardman N, Gill LL, De Winter RF, et al. Generation of a recombinant mouse-human chimaeric monoclonal antibody directed against human carcinoembryonic antigen. Int J Cancer 1989;44:424-33.
25. Buchegger F, Pelegrin A, Hardman N, et al. Different behaviour of mouse-human chimeric antibody F(ab′)2 fragments of IgG1, IgG2 and IgG4 sub-class in vivo. Int J Cancer 1992;50:416-22.
26. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/ human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989;86:4220-4.
27. Meredith RF, LoBuglio AF, Plott WE, et al. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1, k 17-1A monoclonal antibody. J Nucl Med 1991;32: 1162-8.
28. Meredith RF, Khazaeli MB, Plott WE, et al. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992;33:23-9.
29. Goodman GE, Hellstrom I, Yelton DE, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993;36: 267-73.
30. Wong JY, Williams LE, Yamauchi DM, et al. Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial. Cancer Res 1995; 55(Suppl):5929s-34s.
31. Hosono M, Endo K, Sakahara H, et al. Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA). Br J Cancer 1992;65: 197-200.
32. 131I-chimeric mouse/ human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 1991;51:5461-6.
33. Buchegger F, Mach JP, Pelegrin A, et al. Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J Nucl Med 1995; 36:420-9.
34. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm AL, Mellstedt H, Frodin JE. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother 1996;42:81-7.
35. Steinitz M, Klein G, Koskimies S, Makel O. EB virus-induced B lymphocyte cell lines producing specific antibody. Nature 1977;269:420-2.
36. Olsson L, Kaplan HS. Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci U S A 1980;77:5429-31.
37. Del Vecchio S, Carrasquillo JA, Steis R, et al. Imaging of colon cancer with 1-131 28A32 human monoclonal antibody. J Nucl Med 1987;28:636 [abstract].
38. Steis RG, Carrasquillo JA, McCabe R, et al. Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 1990;8:476-90.
39. Koda K, Glassy MC, Chang HR. Generation of human monoclonal antibodies against colon cancer. Arch Surg 1990;125:1591-7.
40. De Jager RL, McCabe RP, Subramanian R, et al. Radioimmunodetection of colorectal carcinoma with a technetium-99m labeled human IgG monoclonal antibody: 88BV59-1: a phase I clinical trial. Proc Am Assoc Cancer Res 1991;32:184.
41. De Jager RL, Abdel-Nabi H, Serafini A, et al. Radioimmunoscintigraphy (RIS) of colorectal cancer with human monoclonal antibody (AB) 88BV59. Antibody Immunoconj Radiophar 1992;5:332.
42. Gulec SA, Serafini AN, Moffat FL, et al. Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2. Cancer Res 1995;55(Suppl):5774s-6s.
43. Abdel-Nabi H, Evans N, Farrell E, et al. Colorectal carcinoma tumor targeting with elevated human anti-mouse antibody (HAMA) levels. Antibody Immunoconj Radiophar 1992;5:352.
44. Denton GW, Durrant LG, Hardcastle JD, Austin EB, Sewell HF, Robins RA. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1994;57:10-4.
45. Chang HR, Chavoshan B, Park H. Human monoclonal antibody SK1-mediated cytotoxicity against colon cancer cells. Dis Colon Rectum 1993;36:1152-7.
46. Erb K, Borup-Christensen P, Ditzel H, Chemnitz J, Haas H, Jensenius JC. Characterization of a human-human hybridoma antibody, C-OU1, directed against a colon tumor-associated antigen. Hybridoma 1992;11: 121-34.
47. 131I-labeled human monoclonal antibody COU-1 in patients with suspected colorectal carcinoma. Cancer Res 1993;53:5920-8.
48. Goldenberg DM, Ford EH, Lee RE, et al. Cancer imaging with a new 99m-Tc-antibody method [abstract]. J Nucl Med 1989;15:426.
49. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
50. Lane DM, Eagle KF, Begent RH, et al. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br J Cancer 1994;70: 521-5.
51. Siccardi AG, Buraggi GL, Callegaro L, et al. Immunoscintigraphy of adenocarcinomas by means of radiolabeled F(ab′)2 fragments of an anti-carcinoembryonic antigen monoclonal antibody: a multicenter study. Cancer Res 1989;49:3095-103.
52. Serafini AN, Goldenberg DM, Higginbotham-Ford EA, et al. A multicenter trial of cancer imaging with fragments of CEA monoclonal antibodies. J Nucl Med 1989;30:748.
53. Lamki LM, Patt YZ, Rosenblum MG, et al. Metastatic colorectal cancer: radioimmunoscintigraphy with a stabilized In-111-labeled F(ab′)2 fragment of an anti- CEA monoclonal antibody. Radiology 1990;174: 147-51.
54. Behr TM, Becker WS, Klein MW, Bair HJ, Scheele JR, Wolf FG. Diagnostic accuracy and tumor-targeting kinetics of complete versus fragmented 99mTc-labeled anti-carcinoembryonic antigen antibodies: an intraindividual comparison. Cancer Res 1995;55(Suppl): 5786s-93s.
55. Goldenberg DM, Wlodkowski TJ, Sharkey RM, et al. Colorectal cancer imaging with iodine-123-labeled CEA monoclonal antibody fragments. J Nucl Med 1993; 34:61-70.
56. Lechner P, Lind P, Binter G, Cesnik H. Anticarcinoembryonic antigen immunoscintigraphy with a 99mTc-Fab′ fragment (Immu 4) in primary and recurrent colorectal cancer: a prospective study. Dis Colon Rectum 1993;36:930-5.
57. Moffat FL Jr, Vargas-Cuba RD, Serafini AN, et al. Radioimmunodetection of colorectal carcinoma using technetium-99m-labeled Fab′ fragments of the IMMU-4 anti-carcinoembryonic antigen monoclonal antibody. Cancer 1994;73(Suppl):836-45.
58. Murray JL, Rosenblum MG, Zhang HZ, et al. Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab′)2 in colorectal cancer patients. Cancer 1994;73(Suppl):850-7.
59. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965; 122:461-85.
60. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384-6.
61. Mach JP, Buchegger F, Forni M, et al. Use of radiolabeled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today 1981;2:239-49.
62. Abdel-Nabi HH, Schwartz AN, Higano CS, Wechter DG, Unger MW. Colorectal carcinoma: detection with indium-111 anticarcinoembryonic-antigen monoclonal antibody ZCE-025. Radiology 1987;164:617-21.
63. Behr TM, Sharkey RM, Juweid MI, et al. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res 1996;56:1805-16.
64. Granowska M, Jass JR, Britton KE, Northover JM. A prospective study of the use of 111In-labelled monoclonal antibody against carcino-embryonic antigen in colorectal cancer and of some biological factors affecting its uptake. Int J Colorectal Dis 1989;4:97-108.
65. Abdel-Nabi HH, Schwartz AN, Goldfogel G, et al. Colorectal tumors: scintigraphy with In-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic, and immunohistochemical findings. Radiology 1988;166:747-52.
66. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994;37:272-7.
67. Beatty JD, Duda RB, Williams LE, et al. Preoperative imaging of colorectal carcinoma with 111In-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 1986;46:6494-502.
68. Abdel-Nabi HH, Chan HW, Doerr RJ. Indium-labeled anti-colorectal carcinoma monoclonal antibody accumulation in non-tumored tissue in patients with colorectal carcinoma. J Nucl Med 1990;31:1975-9.
69. Bosslet K, Steinstrasser A, Schwarz A, et al. Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas. Eur J Nucl Med 1988;14:523-8.
70. Hertel A, Baum RP, Lorenz M, Baew-Christow T, Encke A, Hor G. Immunoscintigraphy using a technetium-99m labelled monoclonal anti-CEA antibody in the follow-up of colorectal cancer and other tumours producing CEA. Br J Cancer Suppl 1990;10:34-6.
71. Richman PI, Bodmer WF. Monoclonal antibodies to human colorectal epithelium: markers for differentiation and tumour characterization. Int J Cancer 1987;39: 317-28.
72. Durbin H, Young S, Stewart LM, et al. An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc Natl Acad Sci U S A 1994; 91:4313-7.
73. Granowska M, Britton KE, Mather SJ, et al. Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody, 1A3, in colorectal cancer. Eur J Nucl Med 1993;20:690-8.
74. Granowska M, Mather SJ, Britton KE. Diagnostic evaluation of 111In and 99mTc radiolabelled monoclonal antibodies in ovarian and colorectal cancer: correlations with surgery. Int J Rad Appl Instrum [B] 1991;18: 413-24.
75. Colcher D, Hand PH, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci U S A 1981;78: 3199-203.
76. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res 1986;46:850-7.
77. Kuroki M, Fernsten PD, Wunderlich D, et al. Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies. Cancer Res 1990;50:4872-9.
78. Esteban JM, Colcher D, Sugarbaker P, et al. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer 1987;39:50-9.
79. Abdel-Nabi H, Doerr RJ, Chan HW, Balu D, Schmelter RF, Maguire RT. In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results. Radiology 1990;175:163-71.
80. Winzelberg GG, Grossman SJ, Rizk S, et al. Indium-111 monoclonal antibody B72.3 scintigraphy in colorectal cancer: correlation with computed tomography, surgery, histopathology, immunohistology, and human immune response. Cancer 1992;69:1656-63.
81. Kostakoglu L, Divgi CR, Hilton S, et al. Preselection of patients with high TAG-72 antigen expression leads to targeting of 94 percent of known metastatic tumor sites with monoclonal antibody I-131-CC49. Cancer Invest 1994;12:551-8.
82. Guadagni F, Roselli M, Cosimelli M, et al. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer 1993;72:2098-106.
83. Muraro R, Kuroki M, Wunderlich D, et al. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res 1988; 48:4588-96.
84. Arnold MW, Schneebaum S, Berens A, et al. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody. Ann Surg 1992;216:627-32.
85. Schlom J, Eggensperger D, Colcher D, et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992;52:1067-72.
86. Gallinger S, Reilly RM, Kirsh JC, et al. Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. Cancer Res 1993;53: 271-8.
87. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A 1979;76:1438-52.
88. Steplewski Z, Chang TH, Herlyn M, Koprowski H. Release of monoclonal antibody-defined antigens by human colorectal carcinoma and melanoma cells. Cancer Res 1981;41:2723-7.
89. Herlyn D, Sears H, Iliopoulos D. et al. Anti-idiotypic antibodies to monoclonal antibody CO17-1A. Hybridoma 1986;5(Suppl 1):S51-8.
90. Gottlinger HG, Funke I, Johnson JP, Gokel JM, Riethmuller G. The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies. Int J Cancer 1986;38: 47-53.
91. Herlyn D, Herlyn M, Ross AH, Ernst C, Atkinson B, Koprowski H. Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods 1984;73:157-67.
92. Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res 1980;40: 717-21.
93. Herlyn D, Somasundaram R, Zaloudik J, et al. Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer. Cell Biophys 1994:24-25:143-53.
94. 125I-labeled monoclonal antibody 17-1a in human cancer cells. Cancer Res 1989;49:2952-8.
95. Meredith RF, Khazaeli MB, Plott WE, et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. J Nucl Med 1995;36: 2229-33.
96. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group [see comments]. Lancet 1994;343:1177-83.
97. Leinsinger G, Kirsch CM, Denecke H, Pletzer G. Immunoscintigraphy using SPECT and I-131 labeled monoclonal antibodies to CEA/CA 19-9 in the follow-up of colorectal cancer. Antib Immunoconj Radiopharm 1991;4:577-85.
98. Epenetos AA, Nimmon CC, Arklie J, et al. Detection of human cancer in an animal model using radio-labelled tumour-associated monoclonal antibodies. Br J Cancer 1982;46:1-8.
99. Welt S, Divgi CR, Kemeny N, et al. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994; 12:1561-71.
100. Breitz HB, Weiden PL, Vanderheyden JL, et al. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials [see comments]. J Nucl Med 1992;33:1099-109.
101. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
102. Kressner U, Lindmark G, Gerdin B, Pahlman L, Glimelius B. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 1996;16:951-7.
103. Davidson BR, Young H, Waddington WA, et al. Preoperative imaging of colorectal cancers: targeting the epithelial membrane antigen with a radiation-labeled monoclonal antibody. Cancer 1992;69:620-5.
104. Rodriguez-Bigas MA, Bakshi S, Stomper P, Blumenson LE, Petrelli NJ. 99mTc-IMMU-4 monoclonal antibody scan in colorectal cancer: a prospective study. Arch Surg 1992;127:1321-4.
105. Beatty JD, Williams LE, Yamauchi D, et al. Presurgical imaging with indium-labeled anti-carcinoembryonic antigen for colon cancer staging. Cancer Res 1990; 50(Suppl):922s-6s.
106. Bock E, Becker W, Scheele J, Wolf F. Diagnostic accuracy of 99mTc-anti-CEA immunoscintigraphy in patients with liver metastases from colorectal carcinoma. Nuklearmedizin 1992;31:80-3.
107. Behr T, Becker W, Hannappel E, Goldenberg DM, Wolf F. Targeting of liver metastases of colorectal cancer with IgG, F(ab′)2, and Fab′ anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics. Cancer Res 1995;55(Suppl):5777s-85s.
108. Bischof-Delaloye A, Delaloye B, Buchegger F, et al. Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study. J Nucl Med 1989; 30:1646-56.
109. Beatty JD, Hyams DM, Morton BA, et al. Impact of radiolabeled antibody imaging on management of colon cancer. Am J Surg 1989;157:13-9.
110. Corbisiero RM, Yamauchi DM, Williams LE, Esteban JM, Odom-Maryon T, Beatty JD. Comparison of immunoscintigraphy and computerized tomography in identifying colorectal cancer: individual lesion analysis. Cancer Res 1991;51:5704-11.
111. Moffat FL Jr, Pinsky CM, Hammershaimb L, et al. Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab′ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J Clin Oncol 1996;14: 2295-305.
112. Divgi CR, McDermott K, Griffin TW, et al. Lesion-by-lesion comparison of computerized tomography and indium-111-labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trial. J Nucl Med 1993;34:1656-61.
113. Scott AM, Macapinlac HA, Divgi CR, et al. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 1994;35:1976-84.
114. 111In-CYT-103 scanning in recurrent colorectal cancer-does it affect standard management? Dis Colon Rectum 1996;39:514-9.
115. Cornelius E, West B, Forstrom L, Ferguson D, Scheeter L. The lymph node: immunologic functions relevant to radioimmunodiagnosis (RAID) and radioimmunoguided surgery (RIGS). J Nucl Med 1994;35:275P.
116. Duda RB, Zimmer AM, Rosen ST, et al. Radioimmune localization of occult carcinoma. Arch Surg 1990;125: 866-70.
117. Doerr RJ, Abdel-Nabi H, Merchant B. Indium 111 ZCE-025 immunoscintigraphy in occult recurrent colorectal cancer with elevated carcinoembryonic antigen level. Arch Surg 1990;125:226-9.
118. Halpern SE, Dillman RO, Amox D, et al. Detection of occult tumor using indium 111-labeled anticarcinoembryonic antigen antibodies. Arch Surg 1992;127: 1094-100.
119. Patt YZ, Podoloff DA, Curley S, et al. Monoclonal antibody imaging in patients with colorectal cancer and increasing levels of serum carcinoembryonic antigen: experience with ZCE-025 and IMMU-4 monoclonal antibodies and proposed directions for clinical trials. Cancer 1993;71(Suppl):4293-7.
120. Petersen BM Jr, Bass BL, Bates HR, Chandeysson PL, Harmon JW. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer. Am J Surg 1993;165:137-42.
121. Gasparini M, Buraggi GL, Regalia E, Maffioli L, Balzarini L, Gennari L. Comparison of radioimmunodetection with other imaging methods in evaluating local relapses of colorectal carcinoma. Cancer 1994; 73(Suppl):846-9.
122. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-6.
123. Martin DT, Hinkle GH, Tuttle S, et al. Intraoperative radioimmunodetection of colorectal tumor with a hand-held radiation detector. Am J Surg 1985;150: 672-5.
124. Dawson PM, Blair SD, Begent RH, Kelly AM, Boxer GM, Theodorou NA. The value of radioimmunoguided surgery in first and second look laparotomy for colorectal cancer. Dis Colon Rectum 1991;34:217-22.
125. Burak WE Jr, Schneebaum S, Kim JA, et al. Pilot study evaluating the intraoperative localization of radiolabeled monoclonal antibody CC83 in patients with metastatic colorectal carcinoma [see comments]. Surgery 1995;118:103-8.
126. Sardi A, Workman M, Mojzisik C, Hinkle G, Nieroda C, Martin EW Jr. Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system). Arch Surg 1989;124:55-9.
127. Cohen AM, Martin EW Jr, Lavery I, et al. Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer. Arch Surg 1991;126:349-52.
128. Schneebaum S, Arnold MW, Houchens DP, et al. The significance of intraoperative periportal lymph node metastasis identification in patients with colorectal carcinoma. Cancer 1995;75:2809-17.
129. Cote RJ, Houchens DP, Hitchcock CL, et al. Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49. Cancer 1996;77:613-20.
130. Howell R, Hawley PR, Granowska M, Morris G, Britton KE. Peroperative radioimmunodetection, PROD, of colorectal cancer using 99m-Tc PR1A3 monoclonal antibody. Tumori 1995;81(Suppl):107-8.
131. Curtet C, Vuillez JP, Daniel G, et al. Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody. Eur J Nucl Med 1990;17:299-304.
132. Moffat FL Jr, Vargas-Cuba RD, Serafini AN, et al. Preoperative scintigraphy and operative probe scintimetry of colorectal carcinoma using technetium-99m-88BV59. J Nucl Med 1995;36:738-45.
133. Nieroda CA, Mojzisik C, Hinkle G, Thurston MO, Martin EW Jr. Radioimmunoguided surgery (RIGS) in recurrent colorectal cancer. Cancer Detect Prev 1991;15:225-9.
134. LoBuglio AF, Saleh M, Peterson L, et al. Phase I clinical trial of CO17-1A monoclonal antibody. Hybridoma 1986;5(Suppl 1):S117-23.
135. Douillard JY, Lehur PA, Vignoud J, et al. Monoclonal antibodies specific immunotherapy of gastrointestinal tumors. Hybridoma 1986;5(Suppl 1):S139-49.
136. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985;45:5910-3.
137. Verrill H, Goldberg M, Rosenbaum R, et al. Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: a preliminary report. Hybridoma 1986;5(Suppl 1):S175-83.
138. LoBuglio AF, Saleh MN, Lee J, et al. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. J Natl Cancer Inst 1988; 80:932-6.
139. Mellstedt H, Frodin JE, Masucci G, et al. Monoclonal antibodies (MAb 17-1A) for the treatment of patients with metastatic colorectal carcinomas. Acta Chir Scand Suppl 1989;549:63-70.
140. Pullyblank AM, Guillou PJ, Monson JR. m17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancer. Br J Cancer 1994;70:753-8.
141. Hagan PL, Halpern SE, Dillman RO, et al. Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986;27:422-7.
142. Jain RK. Delivery of molecular medicine to solid tumors. Science 1996;271:1079-80.
143. Baxter LT, Jain RK. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data. Br J Cancer 1996;73:447-56.
144. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Initial trial use of murine monoclonal antibodies as immunotherapeutic agents for gastrointestinal adenocarcinoma. Hybridoma 1986;5(Suppl 1):S109-15.
145. Weiner LM, Steplewski Z, Koprowski H, Sears HF, Litwin S, Comis RL. Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma. Hybridoma 1986;5(Suppl 1): S65-77.
146. Frodin JE, Harmenberg U, Biberfeld P, et al. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas. Hybridoma 1988;7:309-21.
147. Weiner LM, Moldofsky PJ, Gatenby RA, et al. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma. Cancer Res 1988;48:2568-73.
148. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody (MAB) adjuvant therapy of Dukes' C colorectal carcinoma: 7-year update of a prospective randomized trial. Proc Am Soc Clin Oncol 1996;5:444.
149. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
150. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
151. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma [see comments]. N Engl J Med 1991;324:709-15.
152. Schneider-Gadicke E, Riethmuller G. Prevention of manifest metastasis with monoclonal antibodies: a novel approach to immunotherapy of solid tumours [Review]. Eur J Cancer 1995;31A:1326-30.
153. Schöber C, Schultke M, Schlimok G, et al. Open label pitol study of monoclonal antibody 17-1A in combination with 5-Fluorouracil/Levamisole or 5FU/Folinic Acid in patients with advanced colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:229.
154. Markoe AM, Brady LW, Woo D, et al. Treatment of gastrointestinal cancer using monoclonal antibodies. In: Vaeth JM, Meyer JL, eds. The present and future role of monoclonal antibodies in the management of cancer. Vol. 24. Basel: Karger, 1990:214-24.
155. 131I-labeled IMMU-4 F(ab′)2 in patients with advanced colorectal carcinoma. Antibody Immunoconj Radiopharm 1993;6:239.
156. 131I-CC49 in colorectal cancer. Cancer 1994;73(Suppl):1057-66.
157. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med 1995;36:586-92.
158. Yu B, Carrasquillo J, Milenic D, et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol 1996;14:1798-809.
159. Buchegger F, Rojas A, Delaloye AB, et al. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Cancer Res 1995;55: 83-9.
160. Tschmelitsch J, Welt S, Barendswaard E, Yao T-J, Cohen A, Old LJ. Enhanced antitumor activity of combination radioimmunotherapy (131I-monoclonal antibody A33) with chemotherapy (fluorouracil) [abstract]. Proc Am Assoc Cancer Res 1996;37:469.
161. Ballantyne KC, Perkins AC, Pimm MV, et al. Biodistribution of a monoclonal antibody-methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer. Int J Cancer Suppl 1988;2:103-8.
162. Takahashi T, Yamaguchi T, Kitamura K, et al. Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma. Cancer 1988;61:881-8.
163. Takahashi T, Yamaguchi T, Kitamura K, Noguchi A, Honda M, Otsuji E. Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer. Jpn J Cancer Res 1993;84:976-81.
164. Byers VS, Rodvien R, Grant K, et al. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res 1989;49:6153-60.
165. LoRusso PM, Lomen PL, Redman BG, Poplin E, Bander JJ, Valdivieso M. Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer. Am J Clin Oncol 1995;18:307-12.
166. Zalcberg JR, Pietersz G, Toohey B, et al. A phase I/II study of the intralesional injection of ricin-monoclonal antibody conjugates in patients with hepatic metastases. Eur J Cancer 1994;30A:1227-31.
167. Litton MJ, Dohlsten M, Lando PA, et al. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol 1996;26:1-9.
168. Giantonio BJ, Weiner LM, Alpaugh RK, et al. Superantigen based immunotherapy: a phase I trial of the staphylococcal enterotoxin a (SEA) with advanced pancreatic and colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1996;15:443.
169. Penna C, Dean PA, Nelson H. Antitumor x anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases. Cancer Res 1994;54:2738-43.
170. Nieken J, Vershueren RC, Timens W, De Ley L, Mulder NH. Intratumoral (i.t.) bispecific monoclonal antibody (bsmAb) in the treatment of colorectal cancer [abstract]. Proc Am Assoc Cancer Res 1995;36:496.
171. Liesveld JL, Frediani KE, Winslow JM, Duerst RE. Abboud CN. Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity. J Cell Biochem 1991;45:381-90.
172. Ragnhammar P, Fagerberg J, Frodin JE, et al. Effect of monoclonal antibody 17-IA and GM-CSF in patients with advanced colorectal carcinoma-long-lasting, complete remissions can be induced. Int J Cancer 1993;53:751-8.
173. Ragnhammar P, Fagerberg J, Frodin JE, Wersall P, Hansson LO, Mellstedt H. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies. Cancer Immunol Immunother 1995;40:367-75.
174. Saleh MN, LoBuglio AF, Wheeler RH, et al. A phase II trial of murine monoclonal antibody 17-IA and interferon-gamma: clinical and immunological data. Cancer Immunol Immunother 1990;32:185-90.
175. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. Cancer Res 1995;55:4339-46.
176. Foon KA, Chatterjee S, Chakraborty M, John WJ, Sherratt A, Bhattacharaya-Chatterjee M. Anti-idiotype antibody vaccine (3H1) that mimics the carcinoembryonic antigen (CEA) as adjuvant treatment [abstract]. Proc Am Soc Clin Oncol 1996;15:554.
177. Pervin S, Sherratt A, Wang H-T, et al. Proliferation of T-cells from colon cancer patients by peptides based on the structure of an anti-idiotype antibody mimicking CEA. Proc Am Assoc Cancer Res 1996;37:473-474.
178. Ciardiello F, Damiano V, Bianco C, et al. Antitumor activity of anti-epidermal growth factor receptor (EGFR) 225 monoclonal antibody (mAb) in combination with 8-CI-cAMP in human colon cancer xenografts. Proc Am Soc Clin Oncol 1996;15:499.